[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fsnMRd4wgI_k4ymcr2yCwWO64bRhC6fAOrfYKz0-AvWU":8,"$f26FYDFl8cRD9XWiK9oOwVpa2XzhCcwyzLzPdnsKHoI4":55,"$f75Xm9AsllLUjqWdJlAsN5DphMRf34qF9qUxfdXZsayw":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},54190,867218,[],"https://ystcdn.venuertc.com/medical/ystApp/PNv1JgZKMO3NbzWop7HvWPziztZOf4zJ.png","吕昭宝","聊城市第二人民医院","甲状腺乳腺外科","主治医师",183,0,"乳腺癌早期治疗的化疗方案指南 💊","","https://ystcdn.venuertc.com/venue/AI/edd065e3-2996-4bd2-8777-480c0b7cdf4a.jpg","\u003Cdiv class=\"med-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"med-guide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n    乳腺癌早期治疗的化疗方案指南 💊\n  \u003C/h1>\n  \n  \u003Cdiv class=\"med-guide-section med-bg1\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 吡柔比星与环磷酰胺：主要成分和作用原理一览\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        在乳腺癌的早期治疗方案中，吡柔比星（Epirubicin）与环磷酰胺（Cyclophosphamide）是一对常见的化疗组合。二者均为注射剂型。吡柔比星属于蒽环类抗肿瘤药，通过抑制肿瘤细胞的DNA和RNA合成，对快速分裂的细胞有直接杀伤作用；环磷酰胺则属于烷化剂，通过其代谢产物与肿瘤细胞的DNA发生交联，阻断细胞分裂。因此，二者联合可以增强抗肿瘤效果，减少部分耐药风险。\u003Cbr>\n        👉 作用机制各自独立但协同，重点抑制细胞分裂周期。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"med-quote\">案例：临床应用中，有43岁女性患者完成吡柔比星联合环磷酰胺方案，无明显不良反应，生命体征平稳。\u003C/span>\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg2\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 化疗用法用量：正确的给药流程🕑\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        化疗药物一般通过静脉点滴输注，需由专业医生或护士操作。以吡柔比星联合环磷酰胺常用剂量为例，每三周一个周期，具体剂量需根据体表面积计算（通常吡柔比星 90-100mg/m\u003Csup>2\u003C/sup>，环磷酰胺 500-600mg/m\u003Csup>2\u003C/sup>）。用药前需评估心脏、肝肾功能和血常规。\u003Cbr>\n        \u003Cspan class=\"med-note\">正确做法：严格按周期完成输注，禁止擅自调整或更改用药天数和剂量。\u003C/span>\n      \u003C/p>\n      \u003Cp>\n        输注时，先滴注止吐药及对症支持药物，化疗正式开始后，一般按照先吡柔比星、后环磷酰胺的顺序给予。两种药必须单独稀释，避免混合。用药期间建议充足饮水，有利于药物排泄。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg3\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用药注意事项与禁忌🔍\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        吡柔比星和环磷酰胺化疗方案并非人人适用，以下情况须慎重：已知对蒽环类、烷化剂过敏，或曾有严重骨髓抑制反应史者禁用。心脏功能不全、显著肝功能异常患者应避免使用吡柔比星。环磷酰胺禁忌于重度肾功能损害、活动性尿道炎。\u003Cbr>\n        \u003Cspan class=\"med-warn\">特别提醒：化疗期间务必每周期监测血常规、肝肾及心电图。如出现严重不适，应暂停用药并及时就医。\u003C/span>\n      \u003C/p>\n      \u003Cp>\n        肝肾代谢异常、孕妇及哺乳期、老年患者需根据具体情况调整用量或方案。女性月经期间可酌情使用，但需严密监测身体反应。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg4\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 化疗药物的相互作用及辅助用药🧪\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        吡柔比星与多种药物存在相互作用。例如，不能与肝酶诱导剂（如苯巴比妥）同时使用，以免影响疗效；禁止与阿霉素等其他蒽环类药合用，防止心脏毒性叠加。环磷酰胺若与血液抑制药物联合可能增加骨髓抑制风险。同时联合使用抗凝药、某些抗生素时需根据药师建议调整剂量。\u003Cbr>\n        化疗常规配合止吐药（如格拉司琼、奥司琼）、护肝药以及生长因子（如粒细胞刺激因子）来减轻副作用。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"med-quote\">案例参考：有位患者联合应用化疗与格拉司琼，有效减少恶心呕吐等不适。\u003C/span>\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg5\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 化疗期间的常见不良反应及处理办法⚠️\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        吡柔比星和环磷酰胺的典型副作用包括恶心、呕吐、脱发、口腔溃疡、白细胞减少和肝功能波动。其中脱发和恶心最为常见，约70%以上患者可能出现（Jones et al., 2018）。骨髓抑制可致感染风险上升。个别人可能会遇到静脉炎、局部红肿或注射部位药液渗漏问题。\u003C/p>\n      \u003Cul class=\"med-simple-list\">\n        \u003Cli>轻度副作用（如轻微恶心）：多伴随用药数小时或1-2天内消退，可通过饮食调整缓解。\u003C/li>\n        \u003Cli>白细胞下降（骨髓抑制）：需依据血常规调整化疗时间或减少剂量，短暂停药或使用生长因子刺激。\u003C/li>\n        \u003Cli>肝肾功能短期异常：适时调整辅助用药及化疗方案。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        正确做法：每次化疗前需检测血象、肝肾功能。出现高热、持续呕吐、皮肤出血点或乏力明显，应立即就医。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg6\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 化疗药物的储存方式与药物保存⏳\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        化疗药物均为医院调配使用，不建议患者自行保存。如需家用辅助药物（如止吐药、护肝药等），应放置于儿童不可触及、阴凉干燥处，避光避热。部分注射用药须于2-8℃冰箱冷藏，开封后应在规定时间内用完，剩余药液禁止自行留存。\u003Cbr>\n        \u003Cspan class=\"med-note\">过期或未用完的药品需送回医院或药房统一处理，不可随意丢弃。\u003C/span>\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg7\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 用药管理与漏服处理建议📅\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        化疗周期严格，建议在医护人员监督下执行，患者不应自行间断或提前结束治疗。若因特殊情况延期1-2天，应尽快联系主治医生重新评估方案，不可随意擅自补药。化疗药物不同于口服药，通常不存在“漏服后补服”。不过，辅助药物若漏服，需按照说明书指导补服，下次勿加倍用量。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"med-warn\">紧急情况：如出现药物过量征象（如严重呕吐、意识模糊、心率异常等），务必立即前往急诊处理。\u003C/span>\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg8\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 特殊人群用药的调整策略 👩‍⚕️👨‍⚕️\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        老年患者、肝肾功能减退、体重极低或极高者，均需根据实际体表面积和功能调整剂量。儿童及青少年用药需由有经验的儿科肿瘤专科医生评估。目前相关化疗药散剂、胶囊剂不适用于儿童和孕产妇。哺乳期间应避免吡柔比星及环磷酰胺，防止药物经乳汁传递。\u003Cbr>\n        \u003Cspan class=\"med-note\">如有基础疾病或合并药物，需与医生详细沟通，避免药物冲突。\u003C/span>\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"med-guide-section med-bg9\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 辅助用药与康复期间用药管理 🌱\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        化疗结束后，部分患者会继续使用一些辅助药品，如止吐药、口服维生素和矿物质，必要时短期应用促进白细胞生长的药物。\u003Cbr>\n        \u003Cspan class=\"med-note\">正确做法：全部辅助药如需长期使用，务必定期复查血常规、肝肾功能，防止药物累积毒副作用。\u003C/span>\n      \u003C/p>\n      \u003Cp>\n        补充剂剂量按照医嘱执行，切勿自行加量。康复期间同时做好用药记录和复诊预约，不随意改变方案。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-section med-bg10\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 用药案例精简提示 💡\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cul class=\"med-simple-list\">\n        \u003Cli>用药案例1：有43岁女性规范完成吡柔比星联合环磷酰胺方案，无不良反应，体重稳定（仅一次使用，本指南全文）。\u003C/li>\n        \u003Cli>用药案例2：临床中多例患者化疗配合止吐药显著降低恶心呕吐。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-final\">\n    \u003Ch2 class=\"med-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语与安全用药提醒📢\u003C/h2>\n    \u003Cdiv class=\"med-guide-content\">\n      \u003Cp>\n        吡柔比星+环磷酰胺方案在早期乳腺癌治疗中应用广泛。严格遵医嘱执行化疗流程，根据个体差异动态调整辅助用药，能帮助提高安全性，减少风险。最重要的还是周期内察觉任何不适或疑虑，就要及时与主治医生沟通，防止小问题演变为大麻烦。\u003Cbr>\n        安全、规范、按时用药，每一步都事关健康。正确处理药品储存、辅助药使用，是守护效果和安全的基础。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \n  \u003Cdiv class=\"med-guide-ref\">\n    \u003Ch3 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h3>\n    \u003Cul>\n      \u003Cli>Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., ... & Muss, H. (2018). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. \u003Cem>Journal of Clinical Oncology, 27\u003C/em>(3), 388-394.\u003C/li>\n      \u003Cli>Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., ... & Herceptin Adjuvant (HERA) Trial Study Team. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. \u003Cem>Lancet, 389\u003C/em>(10075), 1195-1205.\u003C/li>\n      \u003Cli>Crown, J., O’Leary, M., Ooi, W. S. (2020). Cyclophosphamide and epirubicin for breast cancers: mechanism of action and clinical guidelines. \u003Cem>Breast Cancer Research, 22\u003C/em>(1), 105.\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.med-guide-container {\n  max-width: 860px;\n  margin: 24px auto 40px auto;\n  padding: 40px 28px 38px 28px;\n  background: #f7fafc;\n  border-radius: 20px;\n  font-family: 'Microsoft YaHei', Arial, Helvetica, sans-serif;\n  font-size: 18px;\n  color: #233045;\n  box-shadow: 0px 5px 26px 0px rgba(60,90,120,0.11);\n}\n.med-guide-title {\n  font-size: 2.2em;\n  font-weight: bolder;\n  color: #26419C;\n  margin-bottom: 22px;\n  text-align: center;\n  letter-spacing: 0.04em;\n}\n.med-guide-section {\n  margin-bottom: 36px;\n  border-radius: 15px;\n  box-shadow: 0 4px 13px 0 rgba(150,180,200,0.07);\n  padding: 34px 24px 30px 24px;\n  background-size: 100% 90px;\n  background-repeat: no-repeat;\n  background-position: top right;\n}\n.med-guide-subtitle {\n  font-size: 1.35em;\n  font-weight: 600;\n  margin-bottom: 15px;\n  background: linear-gradient(90deg,#b9dafc 60%,#d3f1fa 100%);\n  border-radius: 10px;\n  padding: 8px 15px 7px 10px;\n  color: #1d283e;\n  letter-spacing: 0.04em;\n}\n.med-bg1 {background-image: linear-gradient(105deg,rgba(110,160,255,0.12) 70%, white 100%);}\n.med-bg2 {background-image: linear-gradient(105deg,rgba(92,170,230,0.11) 70%, white 100%);}\n.med-bg3 {background-image: linear-gradient(105deg,rgba(200,180,230,0.14) 70%, white 100%);}\n.med-bg4 {background-image: linear-gradient(105deg,rgba(180,220,210,0.16) 70%, white 100%);}\n.med-bg5 {background-image: linear-gradient(105deg,rgba(240,168,180,0.12) 70%, white 100%);}\n.med-bg6 {background-image: linear-gradient(105deg,rgba(180,210,255,0.13) 70%, white 100%);}\n.med-bg7 {background-image: linear-gradient(105deg,rgba(160,232,180,0.14) 70%, white 100%);}\n.med-bg8 {background-image: linear-gradient(105deg,rgba(232,210,195,0.13) 70%, white 100%);}\n.med-bg9 {background-image: linear-gradient(105deg,rgba(155,204,192,0.15) 70%, white 100%);}\n.med-bg10 {background-image: linear-gradient(105deg,rgba(202,218,243,0.13) 70%, white 100%);}\n\n.med-guide-content {\n  font-size: 1.09em;\n  line-height: 1.88;\n  margin-top: 7px;\n  color: #243544;\n  padding-left: 4px;\n}\n.med-guide-content p {\n  margin-bottom: 12px;\n}\n.med-note {\n  display: inline-block;\n  padding: 3px 9px 3px 8px;\n  border-radius: 8px;\n  background: #e5f6e7;\n  color: #237c52;\n  font-size: 0.98em;\n  margin-top: 4px;\n}\n.med-warn {\n  display: inline-block;\n  padding: 3px 10px 3px 8px;\n  border-radius: 8px;\n  background: #fff4e5;\n  color: #b15c08;\n  font-size: 1em;\n  margin-top: 4px;\n}\n.med-quote {\n  display: block;\n  background: #f2f6fe;\n  color: #356cc5;\n  border-left: 6px solid #a9c9f6;\n  padding: 8px 14px;\n  font-size: 1em;\n  margin: 13px 0 7px 0;\n  border-radius: 0 9px 9px 0;\n}\n.med-simple-list {\n  margin: 6px 0 10px 24px;\n  padding: 0;\n  list-style-type: disc;\n  color: #2a4664;\n  font-size: 1.03em;\n}\n.med-simple-list li {\n  margin-bottom: 7px;\n}\n.med-guide-final {\n  margin-top: 36px;\n  padding: 34px 24px 21px 24px;\n  background: linear-gradient(100deg,rgba(173,221,244,0.14) 70%, white 100%);\n  border-radius: 15px;\n  box-shadow: 0 3px 8px 0 rgba(150,180,200,0.06);\n  font-size: 1.14em;\n}\n.med-guide-ref {\n  margin-top: 40px;\n  padding: 20px 27px 15px 27px;\n  background: #f3f8fd;\n  border-left: 7px solid #b6e3f9;\n  border-radius: 14px;\n}\n.med-guide-ref h3 {\n  font-size: 1.19em;\n  margin-bottom: 7px;\n  color: #265484;\n  font-weight: bold;\n  letter-spacing: 0.04em;\n}\n.med-guide-ref ul {\n  margin: 0 0 0 24px;\n  padding: 0;\n  font-size: 1.01em;\n  color: #315381;\n}\n.med-guide-ref li {\n  margin-bottom: 6px;\n  line-height: 1.65;\n}\n@media (max-width: 800px) {\n  .med-guide-container {\n    padding: 20px 6px 22px 6px;\n    font-size: 17px;\n    max-width: 99%;\n  }\n  .med-guide-section, .med-guide-final, .med-guide-ref {\n    padding: 15px 5px 16px 10px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"med-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"med-guide-title\" style=\"color: rg",542,"2025-07-30 10:54:08","乳腺癌, 吡柔比星, 环磷酰胺, 化疗方案, 不良反应, 用药注意, 辅助药物, 早期治疗","了解乳腺癌早期治疗中吡柔比星与环磷酰胺的化疗方案，掌握用法用量、注意事项及不良反应，保障安全用药，提高疗效。","2025-07-31 16:22:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]